AdOM & Sheba Medical Center Launch Ground-Breaking Study to Detect COVID-19 By Non-Invasive Eye Exam

February 3, 2022 7:10 AM

AdOM Advanced Optical Technologies and Sheba Medical Center have launched the world's largest study for the detection of COVID-19 within the surface of the eye by a quick, noninvasive measurement of the tear film by the Tear Film Imager (TFI).LOD, ISRAEL and DOVER, DELAWARE / ACCESSWIRE / February 3, 2022 / AdOM Advanced Optical Technologies LTD., a clinical development and commercial stage ophthalmic medical device company has partnered with...

Read more

Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study

February 2, 2022 9:25 AM

DehydraTECHTM sildenafil delivered 74% more drug at 4 minutes, than the controlKELOWNA, BC / ACCESSWIRE / February 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces positive findings in an animal study evaluating DehydraTECHTM processing of the phosphodiesterase inhibitor ("PDE5 inhibitor") sildenafil, for potential application in the management of...

Read more

Newly Published Data Further Support Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma

February 2, 2022 8:30 AM

Broad, durable, and systemic anti-tumor immunity observed using inCPMV with OX40 agonist antibodiesIntratumoral inCPMV administration in combination with systemic anti-OX40 controlled the progression of the primary as well as secondary untreated tumors70% of animals survived for at least 100 days post tumor challenge without development of recurrence or metastatic diseaseNOVATO, CA / ACCESSWIRE / February 2, 2022 / Mosaic ImmunoEngineering, Inc....

Read more

Hillstream BioPharma Announces Acceptance of Abstract at AACR 2022 Annual Meeting Highlighting HSB-510, a Novel Quatramer-based, First-in-Class Dual Inhibitor of HDAC6 and PI3K-delta Downregulating c-myc Expression

February 1, 2022 9:40 AM

BRIDGEWATER, NJ / ACCESSWIRE / February 1, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced that an abstract highlighting the progress of the Quatramer-based dual-targeted HDAC6/PI3K-delta...

Read more

Aqualung Therapeutic’s ALT-100 Antibody Significantly Reduces ARDS Severity in Both Rat and Porcine (Large Animal) Preclinical Models

February 1, 2022 8:00 AM

TUCSON, AZ / ACCESSWIRE / February 1, 2022 / Aqualung Therapeutics, an early-stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for unchecked inflammation, a characteristic of serious acute diseases; has published a study in Scientific Reports (Tadeo Bermudez lead author) highlighting the effectiveness of the eNAMPT-neutralizing ALT-100 monoclonal antibody (mAb)in reducing Acute Respiratory Distress...

Read more

Medspresso Launches CBD and Functional Mushroom Single Serve Sachets

February 1, 2022 8:00 AM

CAPE TOWN, SA / ACCESSWIRE / February 1, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:Medspresso™ is pleased to announce the launch of its single-serve Super Booster Functional Mushroom Sachets and Active CBD Sachets.Medspresso™ has sourced the highest...

Read more

Applied UV Receives Order from Tennessee Department of Corrections for its Scientific Air S-400 Patented 24/7 Large Air Volume, Whole Room UV-C Pathogen Killing Technology

January 31, 2022 8:00 AM

Order represents entry into a significant new market vertical (prisons and correctional facilities) for the company's pathogen killing technologyMOUNT VERNON, NY / ACCESSWIRE / January 31, 2022 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to...

Read more

Lexaria Provides Annual Letter From the CEO

January 27, 2022 9:35 AM

KELOWNA, BC / ACCESSWIRE / January 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide an annual letter from CEO, Chris Bunka and a thorough strategic update to all stakeholders.Dear Shareholders,Will anyone ever forget 2021? If a global pandemic and unprecedented weather events don't resonate, then perhaps the tectonic changes in...

Read more

Hillstream BioPharma and University of Massachusetts Chan Medical School Announce Research Collaboration using CRISPR and Computational Approaches to Advance The Hillstream Ferroptomic Atlas

January 26, 2022 8:30 AM

Collaboration Aims to Identify Novel Chemogenetic Biomarker Profile of HSB-1216 for Solid TumorsUsing CRISPR Mediated Genome Editing to Uncover Novel Targets and Gene Regulatory Networks in Ferroptosis / Iron Mediated Cell Death (IMCD) PathwaysFurther Elucidate the Mechanism of Action of HSB-1216 in Drug Resistance Tumors using CRISPR and Computational ApproachesBRIDGEWATER, NJ / ACCESSWIRE / January 26, 2022 / Hillstream BioPharma, Inc....

Read more

Edesa Biotech to Join Ontario Bioscience Panel Discussion

January 26, 2022 7:45 AM

TORONTO, ON / ACCESSWIRE / January 26, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to participate in a virtual event at the 2022 OBIO Investment Summit hosted by the Ontario Bioscience Innovation Organization.As part of an industry panel, Dr. Nijhawan is expected to discuss,...

Read more

Thermic Science Begins Digital HUB Upgrading New Client American States University with Full Software Systems Integration to Expand University HUB Operations Internationally, Thermic Wins Big, Begins its University Scholarship Apprentice Program to Hire 1,000 Industry Apprentices Worldwide

January 25, 2022 9:00 AM

NASHVILLE, TN / ACCESSWIRE / January 25, 2022 / Thermic Science International Corporation, formerly known as aka ENDOCAN CORP. (OTC:ENDO) an emerging leader in traditional mergers and acquisitions, business development, and Digital HUB Integration is pleased to announce its newest client and partner American States University. The client partnership is focused on introducing one of the largest Nationwide University Scholarships Programs offered,...

Read more

Preclinical studies show Aqualung Therapeutic’s eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer

January 25, 2022 8:00 AM

TUCSON, AZ / ACCESSWIRE / January 25, 2022 / Preclinical prostate cancer (PCa] studies published in the December 17th, 2021 issue of Pharmaceuticals show Aqualung Therapeutic's ALT-100 mAb to significantly improve overall survival and to reduce distal metastases in SCID mice implanted with human prostate cancer (PCa] cells. Aqualung Therapeutics is an early stage immunotherapeutics company with an anti-inflammatory therapeutic platform to...

Read more

Applied UV Declares Monthly Preferred Stock Dividend

January 25, 2022 8:00 AM

MOUNT VERNON, NY / ACCESSWIRE / January 25, 2022 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of...

Read more

Thermic Science Confirms Industry Forefront 2022 Global Digital Immersion HUB Capabilities Merges Traditional Business and Personal Enhancement Services with Advanced Digital Interactive Real-time Instant Business Services and Information HUB Servicing 100’s of Evolving Industries Worldwide

January 21, 2022 9:35 AM

NASHVILLE, TN / ACCESSWIRE / January 21, 2022 / Thermic Science International Corporation, formerly known as aka ENDOCAN CORP. (OTC:ENDO), has been positioned at the Digital HUB industry forefront with clarity of its 2022 Global Digital Immersion HUB Capabilities.As a Global Digital Immersion HUB leader and Advanced Technology implementation expert for business consulting, product development, and personal services that has a vast list of...

Read more

Viewpoint Molecular Targeting(R) to Present at the Virtual Investor 2022 Top Picks Conference

January 20, 2022 10:00 AM

- Live video webcast presentation on Tuesday, January 25th at 11:00 AM ETCORALVILLE, IA / ACCESSWIRE / January 20, 2022 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that Frances L. Johnson, MD, Chief Executive Officer will participate in the Virtual Investor...

Read more

enVVeno Medical to Present at the Virtual Investor 2022 Top Picks Conference

January 20, 2022 8:30 AM

Live video webcast presentation on Tuesday, January 25th at 1:00 PM ETIRVINE, CA / ACCESSWIRE / January 20, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno, will present at the Virtual Investor 2022 Top Picks Conference on Tuesday, January 25, 2022 at 1:00 PM ET.As part...

Read more

BioInvent & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade

January 20, 2022 2:20 AM

LUND, SWEDEN / ACCESSWIRE / January 20, 2022 / BioInvent International (STO:BINV)Preclinical proof-of-concept data published in the January 20, 2022 edition of the Journal for ImmunoTherapy of Cancer (JITC)BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris:...

Read more

Pressure BioSciences to Participate in FORCE Family Office's January 20th Webinar: Innovations and Advancements in the $4.6 Billion CBD Market

January 19, 2022 11:37 AM

Company Invites Investors, Analysts, and Advisors to Attend Its Real-Time, Interactive Fireside ChatSOUTH EASTON, MA / ACCESSWIRE / January 19, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and services to the worldwide food and beverage, biotherapeutics, and personal wellness industries, among others, today...

Read more

Wuhan General Group Launches Mental Illness Drug Discovery Company Neurai Life Sciences

January 19, 2022 8:00 AM

CAPE TOWN, SA / ACCESSWIRE / January 19, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:Wuhan General Group, Inc./M2Bio Sciences, Inc. is excited to announce the launch of Neurai Life Sciences.Neurai Life Sciences is a pre- and clinical-stage biotechnology company...

Read more

BioInvent: The FDA Grants Orphan Drug Designation to BI-1206 for the Treatment of Follicular Lymphoma

January 19, 2022 3:20 AM

LUND, SWEDEN / ACCESSWIRE / January 19, 2022 / BioInvent International (STO:BINV)Clinical data clearly suggest BI-1206 may restore the response to rituximabBioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that its anti-FcyRllB antibody BI-1206 has been granted Orphan Drug...

Read more